NCT07168291 2025-09-17
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
17 trialsNCT05779930 2025-08-15
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06976437 2025-07-10
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Affiliated Hospital of Jiangsu University
Phase EARLY_PHASE1 Recruiting
NCT06716164 2024-12-04
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT06693973 2024-11-19
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT02981914 2024-04-22
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
University of Chicago
Phase EARLY_PHASE1 Completed
NCT05673447 2023-08-28
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Changhai Hospital
Phase EARLY_PHASE1 Unknown
NCT05105867 2023-05-10
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
NCT05739227 2023-02-22
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT05015972 2022-11-29
UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Withdrawn
NCT04697290 2022-02-14
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.
Beijing Tsinghua Chang Gung Hospital
Phase EARLY_PHASE1 Suspended
NCT04412174 2020-06-02
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
Hebei Yanda Ludaopei Hospital
Phase EARLY_PHASE1 Unknown
NCT04264039 2020-02-11
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04169932 2019-11-20
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04028440 2019-09-26
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT02144623 2017-03-03
PREVAIL
Lund University Hospital
Phase EARLY_PHASE1 Completed
NCT00515138 2012-04-12
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
University of California, San Francisco
Phase EARLY_PHASE1 Terminated